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The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is associated with a hyperinﬂammatory state and
lymphocytopenia, a hallmark that appears as both signature and prognosis of disease severity outcome. Although cytokine
storm and a sustained inﬂammatory state are commonly associated with immune cell depletion, it is still unclear whether direct
SARS-CoV-2 infection of immune cells could also play a role in this scenario by harboring viral replication. We found that monocytes,
as well as both B and T lymphocytes, were susceptible to SARS-CoV-2 infection in vitro, accumulating double-stranded RNA
consistent with viral RNA replication and ultimately leading to expressive T cell apoptosis. In addition, ﬂow cytometry and
immunoﬂuorescence analysis revealed that SARS-CoV-2 was frequently detected in monocytes and B lymphocytes from coronavirus
disease 2019 (COVID-19) patients. The rates of SARS-CoV-2-infected monocytes in peripheral blood mononuclear cells from
COVID-19 patients increased over time from symptom onset, with SARS-CoV-2-positive monocytes, B cells, and CD4+ T lymphocytes
also detected in postmortem lung tissue. These results indicated that SARS-CoV-2 infection of blood-circulating leukocytes in
COVID-19 patients might have important implications for disease pathogenesis and progression, immune dysfunction, and virus
spread within the host.
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SARS-CoV-2 productively infects primary human
immune system cells in vitro and in COVID-19
patients

Pontelli et al., J. Mol. Cell Biol. (2022), 14(4), mjac021

In the present study, we investigated the susceptibility and
permissiveness of human PBMCs to SARS-CoV-2. We found that
PBMCs are susceptible and permissive to SARS-CoV-2 infection,
both in vitro and in COVID-19 patients. Furthermore, infection
and cell death of PBMCs may reduce circulating lymphocytes in
infected individuals, directly impacting disease outcomes and
thus contributing to virus dissemination to other organs.
Results
SARS-CoV-2 infects and replicates in human PBMCs in vitro
To determine whether primary cultures of human PBMCs
could be infected with SARS-CoV-2, we obtained PBMCs from
ﬁve healthy donors and inoculated them with virus at an
multiplicity of infection (MOI) of 1. Following 1 h of incubation
at 37°C, cells were washed extensively, incubated for 48 h, and
the viral yield determined at periodic intervals using a 50%
tissue culture infectious dose (TCID50 ) assay (Figure 1A). SARSCoV-2 titers peaked between 6 and 12 hours post-infection
(hpi), with a 100-fold increase from the initial input, followed
by a steady decrease (Figure 1A). Thus, SARS-CoV-2 infection
of PBMCs produced progeny capable of inducing a cytopathic
eﬀect on monolayers of Vero E6 cells. Pretreatment of PBMCs
with ammonium chloride (NH4 Cl), which elevates intracellular
pH and hampers processes such as endosomal acidiﬁcation,
inhibited viral replication, as evidenced by a 10-fold reduction
in SARS-CoV-2 progeny production after 24 h (P = 0.017)
(Figure 1B). This result suggests that SARS-CoV-2 infection in
human PBMCs depends on intracellular acidic pH (Figure 1B).
To evaluate whether NH4 Cl treatment impairs viral entry, we
used a chimeric vesicular stomatitis virus (VSV), in which
the native glycoprotein was substituted by S proteins from
diﬀerent coronaviruses. Treatment of Calu-3 cells with NH4 Cl
similarly reduced the infection by VSV expressing the enhanced
green ﬂuorescent reporter protein (VSV-eGFP) chimeric viruses
expressing SARS-CoV-2-S or Middle East respiratory syndrome
coronavirus S protein (MERS-CoV-S) (Supplementary Figure S1A
and B). Consistent with high levels of TMPRSS2 expression in
Calu-3 cells that can facilitate direct entry of SARS-CoV-2 at
the plasma membrane, NH4 Cl pretreatment did not prevent
VSV-SARS-CoV-2 infection (Hoﬀmann et al., 2020a). As
expected, NH4 Cl inhibited the infection of Calu-3 by VSV,
which requires endosome acidiﬁcation to facilitate G-mediated
membrane fusion. Infection of Calu-3 cells by a chimeric VSV
expressing the fusion and hemagglutinin glycoproteins from
the paramyxovirus parainﬂuenza 5 (PIV5) was unaﬀected
by NH4 Cl, consistent with PIV5 fusing directly at the plasma
membrane.
Even though ACE2 expression in human PBMCs is considered
to be minimal (Dong et al., 2020; Song et al., 2020), we
examined whether SARS-CoV-2 infection was sensitive to the
blockade of ACE2 and TMPRSS2. Pretreatment of PBMCs with the
TMPRSS2 inhibitor Camostat had no overall discernible eﬀect
on virus yields, using either wild-type or ﬂuorescent SARSCoV-2. In contrast, pre-incubation with an antibody blocking
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Introduction
In late 2019, a new coronavirus emerged as the cause of a
severe acute respiratory syndrome named coronavirus disease
2019 (COVID-19). The causal agent, severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2), is classiﬁed in the family
Coronaviridae, genus Betacoronavirus, based on its similarity to
SARS-CoV (Zhou et al., 2020a). Since its emergence, SARS-CoV-2
has become globally distributed, infecting >323 million people,
resulting in 5.5 million deaths (https://covid19.who.int). The
main clinical features of COVID-19 are fever, cough, dyspnea,
anosmia, and dysgeusia, but some patients rapidly evolve
to severe respiratory distress syndrome (Huang et al., 2020;
Vargas-Gandica et al., 2020).
Previous studies identify an inﬂammatory cytokine storm
and lymphocytopenia as hallmarks of severe COVID-19 cases,
with extreme functional exhaustion of T lymphocytes (Diao
et al., 2020; Huang et al., 2020; Zheng et al., 2020). Peripheral
blood mononuclear cells (PBMCs) from COVID-19 patients show
an upregulation of autophagy and apoptosis (Xiong et al.,
2020), suggesting that dampening of the immune system
by SARS-CoV-2 infection might impact disease outcomes. In
addition, a decrease in circulating lymphocytes has been
associated with poor COVID-19 outcomes (Huang et al., 2020).
Still, it remains uncertain whether lymphocytopenia is caused
by intense lymphocyte recruitment to infected sites or by
direct viral infection of lymphocytes, with consequent cell
death.
To initiate infection, the large glycoprotein spike (S) on
the surface of SARS-CoV-2 binds to angiotensin-converting
enzyme 2 (ACE2) on the target cell membrane (Hoﬀmann et al.,
2020b). Upon ACE2 binding, the S protein can be cleaved by
transmembrane protease serine 2 (TMRPSS2), exposing the
fusion peptide and promoting membrane fusion. Fusion occurs
at the plasma membrane or following endocytic uptake with
endosomal cathepsins facilitating the cleavage of S protein at
acidic pH (Hoﬀmann et al., 2020b).
Because ACE2 plays a critical role in viral entry, it is one
of the main factors of cellular tropism (Letko et al., 2020;
Hoﬀmann et al., 2020b). ACE2 expression analysis showed
that the respiratory and gastrointestinal tract, kidney, and
myocardium are ACE2-enriched (To and Lo, 2004; Qi et al.,
2020; Zou et al., 2020). Interestingly, COVID-19 patients’
heart autopsies showed viral particles in cardiomyocytes and
cardiac macrophages (Dolhnikoﬀ et al., 2020; Tavazzi et al.,
2020; Bailey et al., 2021). Single-cell RNA sequencing of
bronchoalveolar lavage ﬂuid (BALF) samples identiﬁed immune
cells harboring SARS-CoV-2 RNA replication intermediates, as
well as antigens in CD3+ cells in lung autopsies. Furthermore,
SARS-CoV-2 antigens were found postmortem in the spleen
and lymph nodes with pathological signs of damage (Xiang et
al., 2021). Together, these pieces of evidence raise essential
questions about whether these immune cells become infected
in the inﬂamed tissues or before reaching secondary lymphoid
tissues.
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Zang et al., 2020). Approximately 30% of PBMCs were
susceptible to VSV-eGFP-mediated infection, and this was
reduced for VSV-SARS-CoV-2-S (12%), VSV-SARS-CoV-S (9%),
and VSV-MERS-CoV-S (20%) (Figure 1F; Supplementary Figure
S1G). These proportions are consistent with what has been
reported for authentic SARS-CoV and MERS-CoV (Li et al., 2003;
Yilla et al., 2005; Chu et al., 2016). Consistent with the cell
types infected by SARS-CoV-2, VSV-SARS-CoV-2-S infects CD14+
monocytes (92%), CD4+ and CD8+ T lymphocytes (2.4% and
2.8%, respectively), and CD19+ B cells (11%) (Figure 1F). We
also used the strategy based on a SARS-CoV-2 infectious clone
(icSARS-CoV-2) engineered to express a replication-dependent
ﬂuorescent protein reporter (Figure 1G) (Xie et al., 2020). At
24 hpi (MOI = 1), 8.6% of the total PBMCs were positive for
the replication reporter. From all the positive live cells, the
most abundantly infected cells were CD14+ monocytes (17%),
followed by CD19+ B cells (15.9%), CD4+ T lymphocytes (4.1%),
and CD8+ T lymphocytes (3.6%). To show that the ﬂuorescent
protein detection was only possible if the virus was viable,
a stock aliquot was ultraviolet (UV)-inactivated, and the lack
of infectivity was conﬁrmed by plaque assay (Supplementary
Figure S1H). The UV-inactivated virus was used in the same
amount as that of infectious viruses to infect PBMCs, and no
ﬂuorescence was detected by ﬂow cytometry (Supplementary
Figure S1I). Together, the data show that SARS-CoV-2 can infect
and replicate in diﬀerent subsets of peripheral blood cells.
SARS-CoV-2 infection of PBMCs in vitro induces apoptosis of T
lymphocytes
As CD4+ and CD8+ T cells were susceptible to SARS-CoV-2
infection, we next investigated whether this could cause cell
death. For this analysis, we infected PBMCs from healthy donors
and monitored the translocated phosphatidylserine (PS) to the
outer leaﬂet of the plasma membrane by annexin-V staining
at 24 hpi. Representative plots are depicted in Figure 2A. In
mock-treated control cells, some basal annexin-V staining was
detected (CD4+ mean 6.24%, CD8+ mean 12.36%) (Figure 2B).
Infection with SARS-CoV-2 resulted in an increase in annexin-V
staining in live CD4+ (89.1% ± 0.9%) and CD8+ T lymphocytes

Figure 1 (Continued) SARS-CoV-2 diﬀerentially infects subsets of human PBMCs in vitro. PBMCs from healthy donors were infected in vitro
with SARS-CoV-2 Brazil/SPBR-02/2020 (MOI = 1) and cultured at 37°C. (A) Replication curve of SARS-CoV-2 with mean (and standard
deviation, SD) of virus titers (in TCID50 /ml) in supernatants from cultures of PBMCs. (B) SARS-CoV-2 progeny titers in supernatants from
infected PBMCs in culture for 24 and 48 hpi, with and without NH4 Cl treatment. (C) Eﬀects on SARS-CoV-2 progeny production by blocking
infection in PBMCs with anti-ACE2 antibody or camostat mesylate, an inhibitor of TMPRSS2. Titers were determined in supernatants at 24
hpi. Progeny titers after treatments were normalized to the progeny titer from untreated PBMCs. (D) Immunoﬂuorescence for SARS-CoV-2 and
dsRNA in PBMCs at 6 hpi with SARS-CoV-2. Cells were immunostained for SARS-CoV-2 (red) and dsRNA (cyan), and then analyzed by confocal
microscopy. Magniﬁcation, 630×. Scale bar, 10 μm. (E) The total frequency and subpopulation’s frequency of SARS-CoV-2-positive cells at
24 hpi with authentic SARS-CoV-2. PBMCs from healthy donors were infected, then at 24 hpi stained with mouse polyclonal anti-SARS-CoV-2,
and analyzed by ﬂow cytometry. (F) The total frequency and subpopulation’s frequency of eGFP-positive cells at 8 hpi with the chimera VSVeGFP-SARS-CoV-2-S virus. (G) The total frequency and subpopulation’s frequency of NeonGreen-positive cells at 24 hpi with the infectious
clone icSARS-CoV-2 mNeonGreen reporter virus. Individual values are plotted with circle signs; histograms depict mean ± SD. The percentage
of each cell subtype was normalized against the total PBMC value. Statistical analysis was done by one-way or two-way analysis of variance
(ANOVA). Tukey’s or Holm–Sidak post-tests were applied when suitable. P-values <0.05 were considered signiﬁcant.
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ACE2 reduced virus titers 5-fold over 24 hpi (P = 0.0016)
(Figure 1C). Conversely, there was no signiﬁcant reduction in
virus yield when PBMCs were pre-treated with unrelated isotype
control antibodies (Supplementary Figure S1C and D). Similar
treatment also aﬀected the entry of chimeric VSV-SARS-CoV-2-S,
but not VSV-eGFP. Even though the amounts of eGFP+ cells were
similar, the lower mean ﬂuorescent intensity in infected PBMCs
suggests that the viruses could still enter cells but through
a less eﬃcient pH-independent pathway. Taken together, the
evidence indicates that the infection of PBMCs is not mediated
exclusively by the interaction with ACE2 and in a pH-dependent
manner (Supplementary Figure S1E and F).
Coronavirus replication produces several RNA-replicative
intermediates and accumulates double-stranded RNA (dsRNA)
in the cytoplasm of infected cells, thus making a reliable
indicator of virus replicative activity. We, therefore, examined
infected PBMCs for SARS-CoV-2 antigen and dsRNA using
confocal microscopy. SARS-CoV-2 antigen-positive cells were
also positive for dsRNA, and double-positive cells visualized at
6 hpi followed a pattern that roughly matched the accumulation
of virus progeny (Figure 1D). The dsRNA staining was seen
as puncta, consistent with the juxtanuclear staining of viral
replication complexes seen for other coronaviruses (Deng et al.,
2017). Together, these data demonstrate that human peripheral
blood cells are susceptible to infection by SARS-CoV-2 in vitro.
The ﬁnding that human PBMCs can be infected with
SARS-CoV-2 in vitro led us to examine which cell types were
susceptible to infection. PBMCs from healthy donors were
incubated with SARS-CoV-2 at MOI of 1, and the intracellular
expression of SARS-CoV-2 antigens was assessed by ﬂow
cytometry with a polyclonal antibody (Figure 1E). At 24
hpi, 17.7% ± 3.8% of all PBMCs were SARS-CoV-2-positive
(Figure 1E), with CD14+ monocytes representing an average of
53.5% of SARS-CoV-2-positive cells. In addition to monocytes,
CD4+ (10%) and CD8+ (9%) T lymphocytes and CD19+ B cells
(7.58%) were also positive for SARS-CoV-2 antigens. To examine
whether this was unique to SARS-CoV-2, we used chimeric
VSV containing the S genes of MERS-CoV, SARS-CoV, and
SARS-CoV-2 (Fukuma et al., 2015; Hoﬀmann et al., 2020a, b;

Pontelli et al., J. Mol. Cell Biol. (2022), 14(4), mjac021

(48.5% ± 9.5%) (Figure 2B). Diﬀerences were still signiﬁcant
when cells were analyzed independently of live/dead staining.
In the case of CD8+ T cells, the diﬀerence was even greater
(59.64%, P = 0.0001) (Supplementary Figure S2A), indicating
that a considerable percentage of dead CD8+ T cells were
annexin-V-positive. A small reduction in annexin-V staining
was observed in CD4+ and CD8+ T cells after NH4 Cl treatment
(70.88% ± 17.2% and 39.7% ± 16.1%, respectively). In
addition to PS translocation, we evaluated the activation of

caspase 3/7 as indicative of apoptosis. PBMCs from healthy
donors were infected at MOI of 1 with icSARS-CoV-2 and
evaluated at 24 hpi by ﬂow cytometry. Representative plots
are shown in Figure 2C. Quantitatively, 42.73% ± 17.18%
of PBMCs were positive for active caspase 3/7 upon icSARSCoV-2 infection, compared with 75.9% ± 8.3% of PBMCs
induced with staurosporine, a known apoptosis inducer
(Figure 2D). The rates of apoptotic cells in PBMCs exposed to UVinactivated virus (8.7% ± 1.3%) were similar to the rates seen in
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Figure 2 SARS-CoV-2 activates caspase 3/7 and increases the expression of cell death markers. (A) Representative ﬂow cytometry plots of
live CD4+ and CD8+ T cells positive for annexin-V staining in PBMCs at 24 hpi with SARS-CoV-2 (MOI = 1), in the presence or absence of NH4 Cl.
(B) Percentages of live lymphocytes positive for annexin-V and expressing PS at the cell surface after SARS-CoV-2 infection. (C) Representative
plots of PBMCs presenting active caspase 3/7. Cells from healthy donors were infected with mock (in the absence or presence of the apoptosis
inducer staurosporine), icSARS-CoV-2 (MOI=1), or UV-inactivated icSARS-CoV-2. At 24 hpi, cells were labelled with the ﬂuorochrome-labelled
inhibitors of caspases (FLICA) substrate 660-DEVD-FMK and analyzed by ﬂow cytometry. (D) Frequencies of active caspase 3/7 in total PBMCs.
SP, staurosporine. (E) Frequencies of T lymphocytes positive for caspase 3/7 (gray) and icSARS-CoV-2 (green) from the total PBMCs. Mean ± SD
is indicated for all bar graphs. Signiﬁcance was determined by two-way ANOVA and Bonferroni’s post-test.
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Circulating immune cells from COVID-19 patients are infected
and harbor SARS-CoV-2 replication
As PBMCs were robustly infected in vitro, we analyzed the
PBMCs from severe COVID-19 patients. Patients’ clinical and
demographic characteristics are listed in Supplementary Table
S1. The PBMCs from 22 of the 29 patients enrolled (seven
samples were discarded due to severe lymphocytopenia)
and 12 healthy donors were analyzed by ﬂow cytometry for
SARS-CoV-2 antigen staining (Figure 3A). Gating strategies for
lymphocytes and monocytes are shown in Supplementary Figure
S3A and B, respectively. SARS-CoV-2 antigens were detected in
7.68% ± 1.56% of PBMCs from COVID-19 patients (Figure 3B).
However, not all COVID-19 patients showed expressive staining
for SARS-CoV-2 in PBMCs, and the rates of SARS-CoV-2-positive
cells ranged from 0.16% to 33.9% (Figure 3B).
We also monitored PMBCs from 15 of the 22 COVID-19
patients for SARS-CoV-2 RNA levels by real-time reverse
transcription–polymerase chain reaction (RT–PCR). Virus
genome was detected in 8 out of 15 patients’ PBMCs
(53.3%), with a mean viral load of 3.8 × 104 copies per μg
RNA (Supplementary Table S2). Immunophenotyping of cells
from COVID-19 patients indicated that the highest proportion
of SARS-CoV-2-positive cells was found in B lymphocytes
(42.73% ± 4.3%). Infection of CD4+ and CD8+ T lymphocytes
corresponded to 1.2% ± 1.19% and 4.93% ± 6.6% of the
positive PBMCs, respectively. A high rate of CD14+ monocytes
(14.19% ± 15.26%) was positive for SARS-CoV-2 antigens.
Specialized inﬂammatory monocytes (CD14+ CCR2+ and
CD14+ CD16+ CCR2+ ) were also positive for SARS-CoV-2
antigens in high frequencies (18.73% ± 18.46% and 14.78% ±
15.5%, respectively) (Figure 3C). We also performed immunoﬂuorescence of patients’ PBMCs and detected SARS-CoV-2 antigens in CD4+ , CD19+ , and CD14+ cells, with no discernible ﬂuorescent signal seen in PBMCs from healthy donors (Figure 3D).
Since rates of SARS-CoV-2-positive cells in PBMCs varied
widely (Figure 3C), 15 COVID-19 patients whose clinical
information was available were stratiﬁed based on the
length of time between symptom onset and PBMC collection,
and the rates of SARS-CoV-2-positive cells of diﬀerent
immunophenotypes were plotted on a heat map (Figure 3E).

The rates of SARS-CoV-2-positive B lymphocytes were high
in PBMCs collected at all time points, whereas the rates of
SARS-CoV-2-positive monocytes were higher at more extended
time points of COVID-19 progression (Figure 3E). Frequencies of
SARS-CoV-2-positive cells correlated positively with the length
of time of COVID-19 progression, especially for inﬂammatory
CD14+ CCR2+ monocytes (r = 0.442, P = 0.044) (Figure 3F).
To see whether SARS-CoV-2 was actively replicating in PBMCs
from COVID-19 patients, we analyzed the presence of dsRNA
in SARS-CoV-2-positive cells of diﬀerent immunophenotypes
by immunoﬂuorescence and confocal microscopy. Staining for
dsRNA was found in SARS-CoV-2-positive CD4+ T lymphocytes,
B lymphocytes, and monocytes (Figure 4). Similar results were
attained by ﬂuorescent in situ hybridization using an N2 oligonucleotide probe speciﬁc for the SARS-CoV-2 antigenome, which
yielded a strong signal in a pattern typical of viral replication
sites in the cytoplasm (Supplementary Figure S4). Altogether,
these data conﬁrm that SARS-CoV-2 infects and replicates in
circulating lymphomononuclear cells in COVID-19 patients.
SARS-CoV-2-positive inﬂammatory monocytes and lymphocytes
are detected postmortem in lung tissues from COVID-19
patients
Considering that SARS-CoV-2 is a major respiratory
pathogen, we next examined whether SARS-CoV-2-infected
cell immunophenotypes found in PBMCs were also present
in lung autopsy samples. Postmortem lung specimens from
COVID-19 patients revealed abundant staining for SARS-CoV-2,
especially throughout the bronchi–vascular axes and alveolar–
capillary barriers. No staining was detected in control lung
specimens (Supplementary Figure S5). Upon staining for SARSCoV-2, slides were scanned, then the staining was erased, and
slides were re-stained sequentially for the surface antigens CD4,
CD20, and CD14. The serial immunolabelling showed positivity
for SARS-CoV-2 antigens in CD4+ T lymphocytes (Figure 5A), B
lymphocytes (Figure 5B), and monocytes (Figure 5C) in lungs
from COVID-19-infected individuals. Based on its role in lung
tissue damage in COVID-19 patients, interleukin-6 (IL-6) was
also detected by immunostaining, which revealed that several
CD14+ monocytes expressing IL-6 were positive for SARS-CoV-2
antigens (Figure 5D), indicating that SARS-CoV-2 also infects
inﬂammatory monocytes in the lungs of COVID-19 patients.
Discussion
SARS-CoV-2 has an extensive tissue tropism accessed
following entry from the respiratory tract (Dong et al., 2020).
Dissemination of the virus may reﬂect circulating cells that could
serve as ‘Trojan horses’ transporting the virus to secondary
target organs and driving extrapulmonary COVID-19-related
injury. Consistent with such a model, we recently reported that
SARS-CoV-2 infects neutrophils that could carry SARS-CoV-2
into tissues upon recruitment (Veras et al., 2020). SARS-CoV-2
was also detected in monocytes from severe COVID-19 patients
with inﬂammasome activation (Rodrigues et al., 2020). It
remained unclear whether SARS-CoV-2 infects other kinds
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mock-infected PBMCs (10.5% ± 3.8%) (Figure 2D). This indicates that a viable replicating virus is needed to induce apoptosis in these cells. Among PBMCs, T lymphocytes accounted
for most of the caspase 3/7-positive cells. CD4+ T lymphocytes
comprised 49.2% ± 2.3% of the cells with active caspase 3/7,
followed by CD8+ T cells (21% ± 3%) (Figure 2E). The positivity
rates for active caspase 3/7 were similarly low in B cells (1.8%
± 0.4%) and monocytes (1.1% ± 0.4%) (Supplementary Figure
S2B). Only ∼6.7% of CD4+ and 2% of CD8+ T cells were simultaneously positive for active caspase 3/7 and icSARS-CoV-2,
suggesting that apoptosis induction occurs independently
of viral replication in these cells (Figure 2E). Taken together,
the results indicate that SARS-CoV-2 induces apoptosis and
increases cell death markers in circulating T lymphocytes.

Pontelli et al., J. Mol. Cell Biol. (2022), 14(4), mjac021
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Figure 3 Detection of SARS-CoV-2 in PBMCs from hospitalized COVID-19 patients. Twenty-two ICU-hospitalized COVID-19 patients presenting
a moderate to severe condition and 12 age- and gender-matched healthy donors PCR negative for SARS-CoV-2 were enrolled. (A) Representative ﬂow cytometry plots indicating SARS-CoV-2 positivity of PBMCs from COVID-19 patients in comparison with isotype control and healthy
donors. (B) Violin plot showing the frequencies of SARS-CoV-2-infected cells from COVID-19 patients. (C) Percentages of SARS-CoV-2-infected
cells considering diﬀerent immunophenotypes in COVID-19 patients. (D) Immunoﬂuorescence of PBMCs from COVID-19 patients labelling
for SARS-CoV-2 (red), nuclei (blue), and immunophenotypes as CD4, CD19, or CD14 (green). Scale bar, 50 μm. (E) Heat map indicating
SARS-CoV-2-positive cell frequencies for each immunophenotype, stratiﬁed by time from symptom onset (patient number/days after symptom
onset). Data were plotted individually for each COVID-19 patient analyzed. (F) Correlation and linear regression analysis between time after
symptom onset and frequencies of SARS-CoV-2-positive cells. Both P and r values are indicated in the graphs. The best-ﬁtting line is displayed
in colors, while the light-colored area represents the conﬁdence interval. P-values <0.05 were considered signiﬁcant.
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of lymphomononuclear cells in vivo. This study deﬁnes the
susceptibility of human PBMCs to SARS-CoV-2 infection and
validates those ﬁndings by direct analysis of cell types from
peripheral blood of COVID-19 patients with advanced disease.
We reached our conclusions based on infection studies
carried out with the authentic SARS-CoV-2, a SARS-CoV-2
infectious clone (icSARS-CoV-2) engineered to express a

replication reporter, and a chimeric VSV-SARS-CoV-2. These
three independent strategies have in common the presence
of the S glycoprotein on the viral surface, deﬁning it as the
key determinant for cell tropism. Our analysis shows that
SARS-CoV-2 infection of PBMCs results in a peak of viral
replication at 12 hpi, yielding ∼100-fold of the input virus. This
modest infection mirrors the kinetics of dsRNA appearance in
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Figure 4 PBMCs from COVID-19 patients present dsRNA, a coronavirus hallmark of replication. PBMCs from healthy donors (A) or
COVID-19 patients (B) were isolated and cultivated on coverslips pre-treated with poly-D-lysine. Cells were ﬁxed and stained for SARSCoV-2 (red), immune phenotypes as CD4, CD19, or CD14 (green), dsRNA (cyan), and nuclei (blue). Immunoﬂuorescence was examined using
confocal microscopy. In the bottom left corner of each channel, an inset of the labelling phenotype is shown. Representative images for each
immunophenotype are shown, where at least two patients were analyzed. Magniﬁcation, 630×. Scale bar, 10 μm.
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Figure 5 SARS-CoV-2 is detected in diverse immune cell types in COVID-19 lung autopsies. (A–C) SARS-CoV-2 antigen detection
(pseudocolored in green) with sequential staining for CD4 (A), CD20 (B), and CD14 (C) surface markers, pseudocolored in red. (D) Staining
for IL-6, pseudocolored in magenta. The overlaid layers from the previous sequential rounds of staining are displayed with superimposed
staining indicated in yellow. Dashed line-boxed areas are zoomed in and shown in right panels. Magniﬁcation, 400×. Scale bar, 50 μm.
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positive correlation between time from symptom onset and frequency of SARS-CoV-2-positive cells in PBMCs. A possible explanation for an increase in SARS-CoV-2-susceptible cells over time
could be an increase in ACE2 expression, triggered by type I interferon (Ziegler et al., 2020). In this context, it is noteworthy that
the replication of another coronavirus, SARS-CoV, in PBMCs was
not sustained for a long period (Li et al., 2003; Yilla et al., 2005).
An intense T cell depletion in peripheral blood is seen in up
to 85% of severe COVID-19 patients (Chen et al., 2020; Huang
et al., 2020). Furthermore, T cells from COVID-19 patients
show multiple levels of exhaustion markers, and transcriptome
analysis of their PBMCs indicated upregulation of genes
involved in apoptosis and p53 signaling pathways (Diao et al.,
2020; Xiong et al., 2020; Zheng et al., 2020). These data suggest
that SARS-CoV-2 infection could induce cell death by apoptosis
in PBMCs, which could also happen in inﬂamed, infected organs
of COVID-19 patients. It is important to note that MERS infection
also implicates lymphopenia due to direct infection of primary
T lymphocytes and induction of apoptosis (Chu et al., 2016).
Exposure of human PBMCs to SARS-CoV-2 rapidly induced
apoptosis in CD4+ and CD8+ T cell populations, as detected
by activation of caspase 3/7, and the translocation of PS, as
seen by annexin-V staining. Interestingly, UV inactivation of
SARS-CoV-2, as well as a lesser extent of treatment with NH4 Cl,
prevented apoptosis in these cells. UV irradiation is widely used
for viral inactivation by causing pyrimidine nucleotide dimerization while keeping the native structure of proteins (Lo et al.,
2021; Loveday et al., 2021). Together, the data indicate that the
induction of apoptosis depends on the viral replication process.
Moreover, caspase 3/7 activation was low in monocytes, consistent with monocytes undergoing pyroptosis after caspase 1
activation by SARS-CoV-2 infection (Rodrigues et al., 2020).
This rapid induction of apoptosis after SARS-CoV-2 exposure
could explain why we did not detect higher numbers of infected
CD4+ T cells in COVID-19 patients, since dying cells are quickly
removed from circulation. The ability of SARS-CoV-2 to trigger
lymphocyte death may explain the observed lymphopenia in
COVID-19 patients. The association of lymphopenia with poor
prognosis is related to the death of speciﬁc T-cell subsets,
resulting in loss of immune response regulatory components
and driving a cytokine storm that can crosstalk with neutrophil
NETosis (Barnes et al., 2020). It is also related to increased
IL-6 and Fas–FasL interactions (Diao et al., 2020), resulting in
severe lymphoid tissue alterations (Blanco-Melo et al., 2020).
SARS-CoV-2 infection recruits signiﬁcant inﬂammatory cell
inﬁltration into the lungs, containing diverse immune cell types
that bear close contact with SARS-CoV-2-infected lung cells,
such as pneumocytes and alveolar macrophages (Martines
et al., 2020). In the present study, we found CD4+ T and B
lymphocytes and, importantly, IL-6-expressing inﬂammatory
macrophages positive for SARS-CoV-2 in the lungs from fatal
cases of COVID-19.
Inﬂammatory monocytes play signiﬁcant roles in the
immunopathology of COVID-19 (Mehta et al., 2020; Zhou
et al., 2020b), and ICU patients have high levels of circulating
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infected PBMCs and is consistent with previous data showing
that SARS-CoV replication in human PBMCs is not sustained for
an extended period (Li et al., 2003). This is also in keeping with
a study that showed SARS-CoV-2 virus-like particles in CD4+ T
cells at as early as 6 and 12 hpi (Banerjee et al., 2020).
Several PBMC immunophenotypes were susceptible to in vitro
infection by the three strategies of SARS-CoV-2 in the present
study, with monocytes being the most susceptible, followed by
B lymphocytes and CD4+ and CD8+ T lymphocytes. The slight
variation between results obtained by diﬀerent strategies may
reﬂect the speciﬁcity of viral replication machinery and kinetics.
Primary human monocytes have been reported susceptible to
MERS-CoV and, more recently, to SARS-CoV-2 (Chu et al., 2016;
Rodrigues et al., 2020). In contrast, one study found that among
PBMCs, only CD4+ T cells had SARS-CoV-2 virus-like particles
(Banerjee et al., 2020). In addition, there have been reports
of reduced expression of ACE2 by lymphocytes (Uhlén et al.,
2015). We found that blocking ACE2 signiﬁcantly reduced, but
did not abolish, SARS-CoV-2 production by infected PBMCs. This
suggests that some ACE2-expressing cell types among PBMCs
may contribute disproportionally to the virus progeny production
or that, in the absence of ACE2, viral entry is suboptimal in these
cells. This suboptimal or alternative entry by SARS-CoV-2 could
be through ACE2-independent routes. A recent study showed
that a spike mutation confers the ability to infect human airway
ACE2-negative cells through heparan sulfates and clathrinmediated endocytosis (Puray-Chavez et al., 2021). Another
alternative entry pathway that has been proposed mentions
CD147, which could serve as an alternative virus receptor,
as already reported for SARS-CoV (Chen et al., 2005; Wang
et al., 2020). CD147, also known as basignin, is expressed
in T lymphocyte subsets, although its role in SARS-CoV-2
infection of these cells is unclear (Solstad et al., 2011; Ren
et al., 2021).
Intense lymphocytopenia has been considered an indicator
of severe clinical outcomes in COVID-19. In the present study,
SARS-CoV-2 was detected in PBMCs from COVID-19 patients,
more prominently in B lymphocytes and subpopulations of inﬂammatory monocytes. The predominance of B lymphocytes as
targets of SARS-CoV-2 infection in vivo, in contrast to PBMCs
infected in vitro, may reﬂect natural diﬀerences in susceptibility
of diﬀerent lymphocyte subsets to SARS-CoV-2 infection due
to external cofactors. SARS-CoV entry in B lymphocytes and
monocyte-derived cells can occur via a FcγRII-dependent pathway, facilitated by the presence of antibodies (Kam et al., 2007;
Jaume et al., 2011). A caveat of the present study was that
PBMCs were obtained at diﬀerent time points during the COVID19 evolution. The discrepancies in the clinical phases at enrollment could explain the heterogeneity in percentages of SARSCoV-2-positive cells of diﬀerent immunophenotypes observed
among patients. Accordingly, SARS-CoV-2 RNA was not detected
in PBMCs from half of the patients, indicating that SARS-CoV-2
infection in PBMCs may be variable, depending on host factors still unidentiﬁed. Another possible scenario would be the
presence only in later phases of COVID-19, as suggested by the
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Materials and methods
Ethics statement and COVID-19 patients
The study was approved by Conselho Nacional de
Ética em Pesquisa (CONEP; Certiﬁcados de Apresentação
para Apreciação Ética # 30248420.9.0000.5440 and
31797820.8.0000.5440). A total of 29 hospitalized patients
were enrolled, all with clinical and radiological features of
COVID-19 and conﬁrmed SARS-CoV-2 infection by RT–PCR in
respiratory secretions. Clinical features, laboratory results, and
therapies are summarized in Supplementary Table S1. For all
comparisons, 12 age- and gender-matched healthy controls
were enrolled. Written informed consent forms were obtained
from both patients and healthy donors.
Viruses and cells
SARS-CoV-2 Brazil/SPBR-02/2020 was kindly provided by
Prof. Edison Luiz Durigon (ICB-USP, São Paulo). Virus stocks
were made in Vero E6 cells. Virus titration was done by serial
10-fold dilutions inoculated in quadruplicate monolayers of
Vero E6 cells and incubated at 37°C in 5% CO2 . The presence
of cytopathic eﬀect at 4 days post-infection (dpi) similar to that
shown in Supplementary Figure S6A was observed, and titers
were read and expressed as TCID50 (Reed and Muench, 1938).
All experiments with SARS-CoV-2 were done in a biosafety level
3 laboratory (BSL-3) located in the Center for Virus Research
from the University of São Paulo in Ribeirão Preto.
Construction and rescue strategies of VSV-eGFP reporter
chimeric viruses expressing the S protein from pandemic
coronaviruses SARS-CoV, SARS-CoV-2, and MERS-CoV or the
hemagglutinin from PIV5 were previously described (Whelan
et al., 1995; Case et al., 2020; Kral et al., 2020). Reference
sequences to all constructs are described in Supplementary
Table S3. Coronavirus chimera stocks were produced in Vero
TMPRSS2 cells. All chimeras were titrated by decimal serial
dilution, and ﬂuorescent foci were counted using a Typhoon
plate reader (Amersham). Experiments were performed at a
BSL-2 laboratory at Washington University in St. Louis.
The infectious clone SARS-CoV-2 that expresses the ﬂuorescent protein mNeonGreen (icSARS-CoV-2) was kindly provided

by Michael Diamond and is described in Xie et al. (2020). Viral
working stocks were grown in Vero hACE2/TMPRSS2 and titrated
in Vero E6 by serial 10-fold dilution with a semi-solid overlay. A
portion of the stock was innactivated by exposure to an UV-C irradiation lamp (254 nm wavelength) for 10 min inside a biosafety
cabinet. Stocks and the inactivation conﬁrmation were done by
serial 10-fold dilutions inoculated in Vero E6 monolayers with a
semi-solid overlay. At 3 dpi, the read-out was done by ﬂuorescent focus formation and plaque formation assays. Experiments
were performed in BSL-3 at Washington University in St. Louis.
Isolation, treatments, and infection of PBMCs
Human PBMCs were isolated from COVID-19 patients or
healthy donors by density gradient as previously described
(Rios-Santos et al., 2007; Alves-Filho et al., 2009), washed, and
resuspended in RPMI 1640 medium. All infections were carried
out using 1 × 106 PBMCs at MOI of 1 at room temperature for 1 h
under orbital agitation. For progeny quantiﬁcation experiments,
the inoculum was removed by extensive washing with cold
phosphate-buﬀered saline (PBS), replenished with fresh RPMI
1640 medium with 2% fetal bovine serum (RPMI 2% FBS),
and incubated at 37°C in 5% CO2 . Supernatants from PBMCs
were collected at 0, 6, 12, 24, and 48 hpi and subjected to
serial 10-fold dilutions to determine virus titers by TCID50 . For
experiments assessing entry inhibition, 20 mM NH4 Cl, 10 μM
camostat, anti-ACE2 antibody (0.5 μg/ml, Rhea Biotech, or
20 μg/ml, R&D Systems), and isotype control antibodies IgG
anti-digoxin (Vector laboratories) or IgG anti-RSV (Abcam) were
used to pre-treat PBMCs for 1 h. If not speciﬁed, the treatments
were removed by washing twice with Hank’s balanced salt
solution prior to infection.
Immunoﬂuorescence staining
Coverslips pre-treated with 0.1% poly-lysine were incubated
with isolated PBMCs from patients or healthy donors at 37°C
for 20 min for cell adherence. After that, coverslips were ﬁxed
with 4% paraformaldehyde in PBS for 15 min, washed, and
permeabilized with 0.1% saponin in 1% bovine serum album
(BSA) solution to access intracellular antigens. Detection of
SARS-CoV-2 antigens was done using serum from a convalescent
COVID-19 patient (Supplementary Figure S1B). In each
experiment using the COVID-19 serum, uninfected PBMCs
and SARS-CoV-2-infected Vero cells were used as negative and
positive controls, respectively. In addition, a human serum
collected in 2016 was used as a negative control. Biotinconjugated anti-human IgG was used as a secondary antibody,
followed by TSA Cyanine 3 System ampliﬁcation. To determine
the types of SARS-CoV-2-infected cells, we used antibodies
for CD4, CD8a, CD14, CD19, and CD20. To detect dsRNA
complexes indicative of virus replication, we used a mouse
monoclonal anti-dsRNA J2 antibody, which binds to dsRNA
of 40 bp or longer. Secondary antibodies are described in
Supplementary Table S3. The Golgi complex staining and nuclei
staining were performed with mouse anti-GM130 antibody
and 4 ,6-diamidino-2-phenylindole (DAPI) dihydrochloride dye,

Page 11 of 14

Downloaded from https://academic.oup.com/jmcb/article/14/4/mjac021/6572370 by Washington University School of Medicine Library (M1) user on 03 January 2023

CD14+ CD16+ inﬂammatory monocytes, which also correlates
with unfavorable outcomes (Zhou et al., 2020b; Zhang et al.,
2021). Increased expression of CCR2 and other inﬂammatory
markers in monocytes leads to their inﬁltration in tissues with
high expression of the corresponding CCL2 chemokine (Zhou
et al., 2020b). Monocytes with the same proﬁle were found
abundantly in BALF from patients with severe COVID-19 (Liao
et al., 2020). Our data may suggest that SARS-CoV-2-infected
CD14+ CCR2+ and CD14+ CD16+ CCR2+ monocytes could act
as ‘Trojan horses’ and traﬃc viruses to secondary sites of
infection, where SARS-CoV-2 causes severe tissue damage.
Further studies will be required to clarify whether SARSCoV-2-positive lymphoid–mononuclear cells in lung tissue
become infected in the lung or migrate into the aﬀected tissue
from the bloodstream already infected.
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respectively. Preparations were analyzed in a Zeiss Confocal
780 microscope in a tile 3 × 3 using a single focal plane. After
imaging, analysis was performed using Fĳi software.

Flow cytometry
PBMCs from COVID-19 patients or healthy donors infected in
vitro with SARS-CoV-2 were surface-stained with a viability dye
and monoclonal antibodies speciﬁc for CD3, CD4, CD8a, CD19,
CD14, CD16, and CCR2 for 30 min at 4°C. Detection of SARSCoV-2 intracellular antigens by ﬂow cytometry was done on
TM
permeabilized PBMCs with the BD Cytoﬁx/Cytoperm kit using
the mouse anti-SARS-CoV-2 polyclonal antibody (described
in Supplementary Materials and methods) diluted 1:300 in
Perm/Wash buﬀer for 15 min at 4°C. Subsequently, cells were
washed with Perm/Wash buﬀer and incubated with anti-mouse
IgG-AlexaFluor488 antibody. In parallel, SARS-CoV-2-infected
cells without permeabilization were also stained as controls
to verify that virus staining was strictly intracellular. As an
additional control, in vitro infected cells were treated with
trypsin for 60 min on ice to remove possible surface-bound
virus particles (false positives) (Supplementary Figure S7).
Surface PS staining and active caspase 3/7 detection were
carried out using commercial kits (described in Supplementary
Table S3) and following the manufacturer’s guidelines. Data
were acquired using FACSVerse, FACS Canto (BD Biosciences),
or Cytek/Aurora spectral ﬂow cytometers (Cytek Biosciences)
for multiparametric cell characterization, virus detection, and
caspase activation assays. Subsequent analysis was done using
FlowJo v.10 (TreeStar) software. Gating strategies are illustrated
in Supplementary Figure S8.
Serial immunohistochemistry
Tissue sections from paraﬃn-embedded lung fragments
obtained postmortem from two COVID-19 fatal cases were
tested by immunohistochemistry (IHC) using anti-SARSCoV-2 mouse polyclonal antibody (described in Supplementary
Materials and methods) diluted 1:100 in PBS containing 1%
BSA and 0.1% saponin. The primary antibody was detected
using a biotinylated secondary antibody. Signal ampliﬁcation
was done by incubation with streptavidin–peroxidase polymer,
and signal development was done with peroxidase. Sequential
immunoperoxidase labelling and erasing (Glass et al., 2009)
was then performed to determine the immunophenotypes of

Supplementary material
Supplementary material is available at Journal of Molecular
Cell Biology online.
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